A Prospective European Trial Comparing Laparotomy, Laparoscopy, Robotic-assisted, and Transanal Total Mesorectal Excision Procedures in High-risk Patients With Rectal Cancer: The RESET Trial

一项前瞻性欧洲试验比较了高危直肠癌患者接受开腹手术、腹腔镜手术、机器人辅助手术和经肛门全直肠系膜切除术的疗效:RESET试验

阅读:2

Abstract

OBJECTIVE: To compare total mesorectal excision (TME) techniques combined with sphincter-sparing procedures in high-risk patients (HRPs). BACKGROUND: TME is the standard treatment for rectal cancer, but it can be challenging in HRPs. The available surgical approaches must be compared, especially in HRPs. METHODS: Prospective, observational, multicenter trial to compare laparotomy (OTME), laparoscopy (LTME), robotic-assisted surgery (RTME), and transanal surgery (TaTME) in HRPs. The composite primary outcome included circumferential radial margin (CRM) ≥1 mm, TME grade II-III, and absence of Clavien-Dindo grade III-IV complications. Three propensity score analyses were performed (LTME vs RTME, RTME vs TaTME, LTME vs TaTME). RESULTS: A total of 1078 HRPs (75% of men, median body mass index of 27 kg/m 2 , 50% of tumors in the lower third of the rectum) underwent surgery. The RTME and TaTME groups included patients with more advanced and lower tumors and coloanal anastomosis ( P <0.001). Operative time was longer for RTME surgery ( P <0.001). The conversion rate was similar for minimally invasive procedures (4.5%). The global R0 resection rate was 96% without difference among techniques. The primary outcome rates were 82.4%, 64.3%, 74.7%, and 80.3% for LTME, OTME, RTME, and TaTME, respectively. None achieved the expected success rate (85%), and propensity score analyses found no differences. Operative results were similar between high-volume and low-volume inclusion centers only for RTME. CONCLUSIONS: The RESET trial yielded high-quality results despite focusing on HRPs. Minimally invasive procedures showed similar sphincter-sparing procedure outcomes, but LTME included patients with more favorable tumors. Oncologic and functional outcomes will be evaluated at 2 years (ClinicalTrials.gov, ID: NCT03574493).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。